retatrutide clinical trials weight loss results π may be redefining obesity treatment. New data from TRIUMPH-1 Trial showed: π₯ ~28% average over 80 weeks π₯ >30% weight loss in nearly half of participant #ObesityMedicine #Retatrutide #GLP1 #CardioMetabolic Have you heard? The Retatrutide
Description
In the USA, an estimated 5 million patients suffer from some form of gastroparesis [23], and the female:male ratio is 4:1 [24, 25]
Ready-to-Drink (RTD) Protein Shakes Subsegment is Driving the GLP-1 Companion Nutrition Market The ready-to-drink (RTD) protein shakes subsegment is emerging as one of the strongest drivers in the GLP-1 companion nutrition market, driven by unmatched convenience and ease of consumption
it means that women and their health care providers are having to make decisions with incomplete information, potentially exposing women to serious risks or missed opportunities to promote health during one of the most physiologically and psychosocially challenging transitions in their lives
Cognitive strategies for reframing Anxiety feeds on catastrophic thinking
Need for Comprehensive Support: The findings highlight the growing interest in expanding GLP-1 use beyond weight loss to address complex health conditions, though providers emphasize the need for training and patient monitoring to support this shift
But it may reduce the inflammatory load enough that the immune system operates closer to its regulation threshold rather than chronically above it
